Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Zendy

Toni K. Choueiri | Zendy; Bernard Escudier | Zendy; Thomas Powles | Zendy; Paul N. Mainwaring | Zendy; Brian I. Rini | Zendy; Frede Donskov | Zendy; Hans J. Hammers | Zendy; Thomas E. Hutson | Zendy; JaeLyun Lee | Zendy; Katriina Peltola | Zendy; Bruce J. Roth | Zendy; Georg A. Bjarnason | Zendy; Lajos Géczi | Zendy; Bhumsuk Keam | Zendy; Pablo Maroto | Zendy; Daniel Y.C. Heng | Zendy; Manuela Schmidinger | Zendy; Philip W. Kantoff | Zendy; Anne E. Borgman-Hagey | Zendy; Colin Hessel | Zendy; Christian Scheffold | Zendy; Gisela Schwab | Zendy; Nizar M. Tannir | Zendy; Robert J. Motzer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Author(s) -

Toni K. Choueiri,

Bernard Escudier,

Thomas Powles,

Paul N. Mainwaring,

Brian I. Rini,

Frede Donskov,

Hans J. Hammers,

Thomas E. Hutson,

JaeLyun Lee,

Katriina Peltola,

Bruce J. Roth,

Georg A. Bjarnason,

Lajos Géczi,

Bhumsuk Keam,

Pablo Maroto,

Daniel Y.C. Heng,

Manuela Schmidinger,

Philip W. Kantoff,

Anne E. Borgman-Hagey,

Colin Hessel,

Christian Scheffold,

Gisela Schwab,

Nizar M. Tannir,

Robert J. Motzer

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1510016

Subject(s) - cabozantinib , medicine , everolimus , hazard ratio , oncology , interim analysis , discontinuation , clinical endpoint , renal cell carcinoma , urology , adverse effect , axitinib , tyrosine kinase inhibitor , sunitinib , surgery , cancer , confidence interval , randomized controlled trial

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research